Canada Markets closed

Preveceutical Medical Inc. (18H.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
0.0160-0.0012 (-6.98%)
At close: 09:14AM CEST
Full screen
Previous Close0.0172
Open0.0160
Bid0.0220 x 0
Ask0.0268 x 0
Day's Range0.0160 - 0.0160
52 Week Range0.0084 - 0.0300
Volume0
Avg. Volume422
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    PreveCeutical Enters into Credit Facility Agreement

    Vancouver, British Columbia--(Newsfile Corp. - July 22, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a $3 million credit facility agreement with the Company's Chief Executive Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders").Effective July 18, 2022, the Company entered into a convertible credit facility agre

  • Newsfile

    PreveCeutical Announces Change in Directors and Investor Awareness Services

    Vancouver, British Columbia--(Newsfile Corp. - May 27, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linnéa Olofsson to the Company's board of directors (the "Board").Resignation of DirectorsMr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus ...

  • Newsfile

    Article Based on PreveCeutical's Pain Management Peptides Program Published in the British Journal of Pharmacology

    Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The art